Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama, 700-8558, Japan.
Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama, Japan.
BMC Cancer. 2022 May 29;22(1):588. doi: 10.1186/s12885-022-09650-w.
The international consensus guidelines for intraductal papillary mucinous neoplasm of the pancreas (IPMN) presented clinical features as indications for surgery. Whereas surveillance for recurrence, including de novo lesions, is essential, optimal surveillance protocols have not been established.
This study aimed to assess the clinical features of recurrence at the remnant pancreas (Rem-Panc) and extra-pancreas (Ex-Panc) after surgery for IPMN. Ninety-one patients of IPMN that underwent detailed preoperative assessment and pancreatectomy were retrospectively analyzed, focusing especially on the type of recurrence.
The IPMNs were finally diagnosed as low-grade dysplasia (LDA, n = 42), high-grade dysplasia (HAD, n = 19), and invasive carcinoma (IPMC, n = 30). Recurrence was observed in 26 patients (29%), of which recurrence was seen at Rem-Panc in 19 patients (21%) and Ex-Panc in 7 patients (8%). The frequency of Rem-Panc recurrence was 10% in LDA, 21% in HDA, and 37% in IPMC. On the other hand, Ex-Panc recurrence was observed only in IPMC (23%). Ex-Panc recurrence showed shorter median recurrence-free survival (RFS) and overall survival (OS) than Rem-Panc recurrence (median RFS 8 months vs. 35 months, p < 0.001; median OS 25 months vs. 72 months, p < 0.001). Regarding treatment for Rem-Panc recurrence, repeat pancreatectomy resulted in better OS than no repeat pancreatectomy (MST 36 months vs. 15.5 months, p = 0.033). On multivariate analysis, main duct stenosis or disruption as a preoperative feature (hazard ratio [HR] 10.6, p = 0.002) and positive surgical margin (HR 4.4, p = 0.018) were identified as risk factors for Rem-Panc recurrence.
The risk factors for Rem-Panc and Ex-Panc recurrence differ. Therefore, optimal surveillance on these features is desirable to ensure that repeat pancreatectomy for Rem-Panc recurrence can be an appropriate surgical intervention.
国际胰腺导管内乳头状黏液性肿瘤(IPMN)共识指南将临床特征作为手术适应证。虽然监测复发(包括新发病灶)至关重要,但尚未建立最佳的监测方案。
本研究旨在评估 IPMN 手术后残留胰腺(Rem-Panc)和胰腺外(Ex-Panc)复发的临床特征。回顾性分析了 91 例接受详细术前评估和胰腺切除术的 IPMN 患者,重点关注复发类型。
IPMN 最终诊断为低级别异型增生(LDA,n=42)、高级别异型增生(HAD,n=19)和浸润性癌(IPMC,n=30)。26 例患者(29%)出现复发,其中 19 例(21%)在 Rem-Panc 复发,7 例(8%)在 Ex-Panc 复发。LDA、HAD 和 IPMC 的 Rem-Panc 复发频率分别为 10%、21%和 37%。另一方面,仅在 IPMC 中观察到 Ex-Panc 复发(23%)。Ex-Panc 复发的中位无复发生存期(RFS)和总生存期(OS)均短于 Rem-Panc 复发(中位 RFS 8 个月 vs. 35 个月,p<0.001;中位 OS 25 个月 vs. 72 个月,p<0.001)。关于 Rem-Panc 复发的治疗,再次胰腺切除术的 OS 优于无再次胰腺切除术(MST 36 个月 vs. 15.5 个月,p=0.033)。多变量分析显示,术前主胰管狭窄或中断(危险比[HR] 10.6,p=0.002)和阳性切缘(HR 4.4,p=0.018)是 Rem-Panc 复发的危险因素。
Rem-Panc 和 Ex-Panc 复发的危险因素不同。因此,对这些特征进行最佳监测,以确保 Rem-Panc 复发的再次胰腺切除术是一种适当的手术干预。